Arkolith/Insider Trading/ACRV/Form 4

Gamelin Erick

Chief Development OfficerAcrivon Therapeutics, Inc. (ACRV) · full profile →Form 4 · filed May 18, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 14, 2026Tax withholding(F)404$1.92$77614K

Transaction Codes

F
Shares withheld for taxes

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000905148-26-002500) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML